They found that modulators down-regulate CF-related exaggerated pro-inflammatory responses differently: whereas IL-18 liberation significantly declines with each combination, only ivacaftor/tezacaftor reduces the IL-1β response. Here, IL1B is linked to cystic fibrosis.